Skip to main content

Table 2 Mean changes in cognitive and functional scores for each quartile of the galantamine plasma concentration

From: Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application

Galantamine plasma concentration after 2 months of treatment (n= 47) Change in MMSE score after 2 monthsa Galantamine plasma concentration after 6 months of treatment (n= 41) Change in MMSE score after 6 monthsa Change in ADAS-cog score after 6 monthsa Change in IADL score after 6 monthsa
Quartile 1,
< 0.143 μmol/L
0.42 (-1.17, 2.01) Quartile 1,
< 0.152 μmol/L
1.50 (-0.16, 3.16) -1.90 (-5.51, 1.71) -0.20 (-1.36, 0.96)
Quartile 2,
0.143 to 0.205 μmol/L
0.25 (-1.11, 1.61) Quartile 2,
0.152 to 0.225 μmol/L
-0.36 (-1.33, 0.60) 0.36 (-1.12, 1.84) -2.56 (-4.73, -0.38)
Quartile 3,
0.205 to 0.279 μmol/L
0.67 (-0.58, 1.92) Quartile 3,
0.225 to 0.267 μmol/L
-0.60 (-2.19, 0.99) -0.22 (-4.34, 3.90) -2.89 (-6.36, 0.58)
Quartile 4,
> 0.279 μmol/L
-0.36 (-1.81, 1.09) Quartile 4,
> 0.267 μmol/L
0.50 (-1.74, 2.74) -0.20 (-2.25, 1.85) 0.00 (-1.15, 1.15)
  1. aMean (95% confidence interval). No significant differences in cognitive or functional changes were found among the patients in the different quartiles of the plasma concentration. ADAS-cog, Alzheimer's Disease Assessment Scale-cognitive subscale; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination.